Angiotech Pharmaceuticals, Inc.
http://www.angiotech.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Angiotech Pharmaceuticals, Inc.
Keytruda Cements Cervical Cancer Leadership With First-Line Nod
Although the label’s PD-L1 expression requirement could limit the addressable market, there is also potential for future combination with Seagen’s recently approved Tivdak.
Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Orphazyme Wants More Time To Deal With Late-Stage Issues For Arimoclomol In EU
Following Orphazyme’s disappointment in the US regarding its investigational drug for an ultrarare disease, the company has said it will need more time to address outstanding issues raised by EU reviewers about the same medicine.
Boehringer & BridgeBio Seek EU Fast-Track Status; Enfortumab Vedotin Reverts To Standard Review
Applications for the accelerated assessment of planned EU marketing applications for two drugs are being considered by the European Medicines Agency.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Laser
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Quill Medical Inc.
- Surgical Specialties Corporation, Inc.